Clinical Trials Browser

Interventional × Lung Neoplasms × MLN 8237 × Clear all

NCT04479306 2026-04-16

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02293005 2022-10-04

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Phase 2 Completed

28 enrolled 11 charts

Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma